Which Medtronic business segments will experience the most growth in Q4?

Mackenzie Garrity -   Print  |

Medtronic is expected to release its fourth quarter and fiscal year 2018 financial results May 24, according to Zacks.

Similar to its first, second and third quarter financial results, Medtronic is expected to see growth in all of its business segments. The company attributes its constant growth to therapy innovation, globalization and the increase in its economic value.

Within Medtronic's cardiac and vascular group, the company is expected to maintain its market share while seeing growth from its new therapies. Medtronic's recent FDA approval of the Resolute Onyx 2.0 mm DES will boost this business segment.

Similarly, the minimally invasive therapies group is expected to register steady growth. The growth is due to new products Medtronic launched throughout the year.

Medtronic's restorative therapies group experienced a 5 percent increase for the full year of 2017, and it is expected the business segment will produce similar growth for the full year of 2018. Its recent introductions in the brain therapy space may push the segment to generate the most growth.

More articles on devices and implants:
Zimmer Biomet awarded $13.3M in patent spat with Stryker subsidiary — 3 things to know
DJO names W. Mark Dorris president of bracing and supports, its largest business unit
Zimmer Biomet partners with spine-specific outpatient center: 3 insights

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers